‘Our Mission Has Always Been to Provide Transformative Care That Addresses the Mind, Body and Spirit’
IRVINE, CA / ACCESSWIRE / December 5, 2024 / Alter Behavioral Health is thrilled to announce that the Santa Monica Daily Press (SMDP) has nominated it for the distinguished title of Best Residential Mental Health Treatment Center in 2024. This recognition highlights Alter’s commitment to providing excellent, holistic care to individuals with mental health issues.
Renowned for its personalized approach, Alter integrates evidence-based therapies such as Cognitive Behavioral Therapy (CBT), Dialectical Behavioral Therapy (DBT), and Solutions-Focused Therapy (SFBT) with innovative tools like the Care Predictor Index. This model ensures clients receive tailored treatment supporting sustainable recovery and long-term well-being.
“Our mission has always been to provide transformative care that addresses the mind, body, and spirit,” said Michelle Mullany, Chief Operating Officer for Alter. “This nomination by SMDP reflects our team’s dedication to helping individuals achieve lasting recovery.”
Set in tranquil, thoughtfully designed facilities, Alter provides an ideal environment for healing. From treating conditions like anxiety, depression, PTSD, and bipolar disorder to offering specialized care for co-occurring substance use disorders, Alter’s holistic philosophy empowers clients to rebuild confidence and embrace brighter futures.
This nomination highlights Alter Behavioral Health as a leader in residential mental health treatment, reaffirming its role in setting new standards for compassionate, high-quality care.
For more information, visit www.alterbehavioralhealth.com.
Contact:
Alter Behavioral Health
info@alterbehavioralhealth.com
(866) 609-9503
Contact Information
Natalie Simpson
Marketing Manager
info@tower25.com
310-817-0072
Source: Alter Behavioral Health
View the original press release on accesswire.com
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…